- Home
- INIO vs MDGL Comparison
INIO vs MDGL Comparison
Compare INIO & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INIO | MDGL |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 11.5B |
| IPO Year | 2026 | 2005 |
Fundamental Metrics
Financial Performance| Metric | INIO | MDGL |
|---|---|---|
| Price | $15.20 | $437.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $35.70 | ★ $685.78 |
| AVG Volume (30 Days) | ★ 4.9M | 262.9K |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $46.91 | $59.57 |
| Revenue Next Year | $33.71 | $38.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.58 | $393.61 |
| 52 Week High | $42.95 | $615.00 |
Technical Indicators
Market Signals| Indicator | INIO | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 34.75 | 29.07 |
| Support Level | N/A | $416.21 |
| Resistance Level | $21.86 | $546.29 |
| Average True Range (ATR) | 1.29 | 18.02 |
| MACD | -0.20 | -1.58 |
| Stochastic Oscillator | 8.86 | 1.57 |
Price Performance
Historical ComparisonAbout INIO INNIO N.V. Ordinary Shares
Innio NV is a distributed energy solutions provider that delivers reliable, flexible, transient, decentralized, modular, and efficient power. The group designs, manufactures, and services high-performance power systems under its Jenbacher and Waukesha brands. The company delivers power for applications including data centers, microgrids, grid stabilization, industrial energy, and gas compression.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.